What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical formulations spanning cardiac, diabetic, dermatology and ENT therapy areas, selling both in India and overseas markets. Exports are diversified across African, Latin American, South-East Asian, institutional-tender and Canadian markets, with a Cepha manufacturing block now past breakeven and Canadian sales run through 6 Health Canada-approved product lines. R&D spend is being stepped up to support growing dossier filings, while the company is exploring entry into oncology and hormones alongside inorganic acquisitions in tablet and injectable manufacturing. Materials (35.7% of revenue) and employee costs (18.7%) are the largest cost lines, and management has guided to an INR1,000 crore revenue target with a stated 5-6 month slippage buffer on the original FY28 timeline.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from LINCOLN PHARMA LTD's filed financials and exchange disclosures
LINCOLN PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LINCOLN.
Yes. Over the trailing twelve months LINCOLN PHARMA LTD reported a net profit of ₹96 Cr on revenue of ₹694 Cr.
Yes. The dividend yield is 0.29% at the current price. It paid out 4% of its profit as dividend in FY26.
Effectively yes. It holds ₹17 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, LINCOLN PHARMA LTD ranks 36 of 169 in Pharmaceuticals — cheaper than 79% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session LINCOLN PHARMA LTD moves 0.86% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by LINCOLN PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
